RxDoctor Payments Data

Assem Elfakih, MD

Internal Medicine · Dearborn, MINPI 1881899946

Payments from drug & device makers

$1,464in general payments, 2019–2025

Across 80 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$389
  • Boehringer Ingelheim$293
  • Novo Nordisk$196
  • Ironwood Pharmaceuticals, Inc$176
  • Amgen$159
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65
  • plus $186 from 8 others

What the payments were for

  • Food & beverage$1,45399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,464 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$78,364
Medicare patients
120
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol131$152,234
JardianceEmpagliflozin121$148,179
JanuviaSitagliptin Phosphate90$84,852
JanumetSitagliptin Phos/Metformin Hcl82$77,100
EliquisApixaban80$74,891
SynjardyEmpagliflozin/Metformin Hcl76$67,728
LinzessLinaclotide64$64,137
TrulicityDulaglutide61$61,326
ProliaDenosumab33$54,639
OzempicSemaglutide32$47,759
RybelsusSemaglutide16$35,227
BrilintaTicagrelor25$24,910
EntrestoSacubitril/Valsartan26$22,489
Trijardy XrEmpaglifloz/Linaglip/Metformin26$19,449
TradjentaLinagliptin19$19,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Trijardy Xr, Tradjenta, Glyxambi$293$278,301279 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$389$188,056174 claims
Novo NordiskOzempic, Rybelsus$196$82,98648 claims
Lilly USA, LLCTrulicity, Mounjaro$12$78,20678 claims
PfizerEliquis$31$74,89180 claims
AbbVieLinzess$23$64,13764 claims
AmgenProlia$159$54,63933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →